Buy Rating Maintained for Unicycive Therapeutics Amidst OLC NDA Submission and Strong ...
Maxim Group's Jason McCarthy maintains Buy rating on Unicycive Therapeutics (UNCY) due to the NDA submission for OLC, potential cost savings, and favorable study results. Despite price target reduction due to TDAPA uncertainties, OLC's approval could unlock significant revenue. UNCY's stock has dropped 76.86% over six months.
Reference News
Buy Rating Maintained for Unicycive Therapeutics Amidst OLC NDA Submission and Strong ...
Maxim Group's Jason McCarthy maintains Buy rating on Unicycive Therapeutics (UNCY) due to the NDA submission for OLC, potential cost savings, and favorable study results. Despite price target reduction due to TDAPA uncertainties, OLC's approval could unlock significant revenue. UNCY's stock has dropped 76.86% over six months.